ResMed, a global pioneer in sleep and respiratory health, has unveiled its robust financial performance for the fourth quarter and full fiscal year 2026, alongside ambitious strategic initiatives poised to redefine its market presence. The company reported a remarkable 9% increase in headline revenue, translating to 8% in constant currency, and a significant 16% surge in non-GAAP earnings per share (EPS), fueled by heightened sales volume and enhanced gross margins. These impressive results underscore ResMed's consistent growth trajectory and its unwavering commitment to innovation and operational excellence.
A cornerstone of ResMed's forward-looking strategy involves a concentrated portfolio optimization. The company has announced the divestiture of its MatrixCare business, a move designed to sharpen its focus on core growth areas within sleep health, breathing health, and connected digital home-based healthcare. Simultaneously, ResMed has expanded its therapeutic reach through the acquisition of Noctrix, integrating solutions for restless leg syndrome, a prevalent sleep disorder. Furthermore, in a strong gesture of confidence in its financial health, ResMed has substantially increased its capital return targets for fiscal year 2027, intending to distribute over $1.85 billion to shareholders via accelerated share repurchase programs and a 10% dividend increase. The company's innovative spirit is also evident in its embrace of cutting-edge technologies, leveraging generative AI and wearable partnerships to broaden access to sleep health diagnoses and improve patient engagement.
Despite encountering persistent inflationary pressures and supply chain hurdles, ResMed remains steadfast in its dedication to volume-driven growth and operational efficiency. The company plans to implement strategic, albeit modest, price adjustments while prioritizing manufacturing productivity to offset rising costs. For fiscal year 2027, ResMed has issued an optimistic revenue guidance ranging from $5.75 billion to $5.85 billion, representing a 5% to 7% growth, and non-GAAP EPS guidance of $12.00 to $12.25, indicating a 7% to 10% increase. This outlook reflects a strategic focus on expanding global manufacturing capabilities and continuing to lead the market with advanced devices like the AirSense 11 and innovative fabric mask technologies, ensuring sustained leadership in the ever-evolving healthcare landscape.
ResMed's proactive approach to market challenges, coupled with its strategic investments in technology and patient care, positions the company for enduring success. By continuously adapting and innovating, ResMed not only strengthens its financial standing but also enhances the well-being of patients worldwide, embodying a commitment to progress and positive impact.
